316 related articles for article (PubMed ID: 19681884)
1. Iron overload in thalassaemia intermedia: reassessment of iron chelation strategies.
Taher A; Hershko C; Cappellini MD
Br J Haematol; 2009 Dec; 147(5):634-40. PubMed ID: 19681884
[TBL] [Abstract][Full Text] [Related]
2. Iron overload in non-transfusion-dependent thalassemia: a clinical perspective.
Musallam KM; Cappellini MD; Wood JC; Taher AT
Blood Rev; 2012 Apr; 26 Suppl 1():S16-9. PubMed ID: 22631036
[TBL] [Abstract][Full Text] [Related]
3. Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia.
Porter JB; Davis BA
Best Pract Res Clin Haematol; 2002 Jun; 15(2):329-68. PubMed ID: 12401311
[TBL] [Abstract][Full Text] [Related]
4. Iron Chelation Therapy as a Modality of Management.
Aydinok Y
Hematol Oncol Clin North Am; 2018 Apr; 32(2):261-275. PubMed ID: 29458731
[TBL] [Abstract][Full Text] [Related]
5. Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease.
Voskaridou E; Douskou M; Terpos E; Papassotiriou I; Stamoulakatou A; Ourailidis A; Loutradi A; Loukopoulos D
Br J Haematol; 2004 Sep; 126(5):736-42. PubMed ID: 15327528
[TBL] [Abstract][Full Text] [Related]
6. Treatment of iron overload in thalassemia.
Cianciulli P
Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():208-13. PubMed ID: 19337180
[TBL] [Abstract][Full Text] [Related]
7. Optimizing iron chelation strategies in beta-thalassaemia major.
Porter JB
Blood Rev; 2009 Dec; 23 Suppl 1():S3-7. PubMed ID: 20116637
[TBL] [Abstract][Full Text] [Related]
8. MRI and iron-overload cardiomyopathy in thalassaemia.
Pennell D
Circulation; 2006 Mar; 113(11):f43-4. PubMed ID: 16552847
[No Abstract] [Full Text] [Related]
9. Clinical consequences of iron overload from chronic red blood cell transfusions, its diagnosis, and its management by chelation therapy.
Shander A; Sazama K
Transfusion; 2010 May; 50(5):1144-55. PubMed ID: 20088842
[TBL] [Abstract][Full Text] [Related]
10. Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions.
Chacko J; Pennell DJ; Tanner MA; Hamblin TJ; Wonke B; Levy T; Thomas PW; Killick SB
Br J Haematol; 2007 Sep; 138(5):587-93. PubMed ID: 17610536
[TBL] [Abstract][Full Text] [Related]
11. Iron chelation therapy for patients with myelodysplastic syndrome.
Yeh SP; Yang YS; Yao CY; Peng CT
Hemoglobin; 2009; 33(5):339-45. PubMed ID: 19814680
[TBL] [Abstract][Full Text] [Related]
12. Assessment and treatment of cardiac iron overload in thalassemia.
Aessopos A; Farmakis D; Andreopoulos A; Tsironi M
Hemoglobin; 2009; 33 Suppl 1():S87-92. PubMed ID: 20001638
[TBL] [Abstract][Full Text] [Related]
13. Pathogenesis and management of iron toxicity in thalassemia.
Hershko C
Ann N Y Acad Sci; 2010 Aug; 1202():1-9. PubMed ID: 20712765
[TBL] [Abstract][Full Text] [Related]
14. Optimal management of β thalassaemia intermedia.
Taher AT; Musallam KM; Cappellini MD; Weatherall DJ
Br J Haematol; 2011 Mar; 152(5):512-23. PubMed ID: 21250971
[TBL] [Abstract][Full Text] [Related]
15. Iron absorption in non-transfused iron loading anaemias: prediction of risk for iron loading, and response to iron chelation treatment, in beta thalassaemia intermedia and congenital sideroblastic anaemias.
Pippard MJ; Weatherall DJ
Haematologia (Budap); 1984; 17(1):17-24. PubMed ID: 6724353
[TBL] [Abstract][Full Text] [Related]
16. Pathophysiology of transfusional iron overload: contrasting patterns in thalassemia major and sickle cell disease.
Porter JB
Hemoglobin; 2009; 33 Suppl 1():S37-45. PubMed ID: 20001631
[TBL] [Abstract][Full Text] [Related]
17. The proceedings of the 17th International Conference on Chelation: application of effective chelation therapies in iron loading and non iron loading conditions, and the gap in the prevention and treatment policies on thalassemia between developed and developing countries.
Kontoghiorghes GJ
Hemoglobin; 2009; 33(5):283-6. PubMed ID: 19814673
[TBL] [Abstract][Full Text] [Related]
18. Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): a status quo.
Taher AT; Musallam KM; Viprakasit V; Porter JB; Cappellini MD
Blood Cells Mol Dis; 2014; 52(2-3):88-90. PubMed ID: 24041597
[No Abstract] [Full Text] [Related]
19. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy.
Leitch HA
Leuk Res; 2007 Dec; 31 Suppl 3():S7-9. PubMed ID: 18037416
[TBL] [Abstract][Full Text] [Related]
20. Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.
Gattermann N
Leuk Res; 2007 Dec; 31 Suppl 3():S10-5. PubMed ID: 18037413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
